GlassScriptPhysician profile
Emily A Radcliffe
NPI 1003232539
$7,589.53
in general payments reported to CMS, 2019-2025
48 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,450 · 2022: $1,146 · 2023: $1,689 · 2024: $2,021 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,992 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,992.01 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,058.58 | 2021-2025 | |
| Abbott Laboratories | $697.60 | 2022-2025 | Freestyle Libre 3, Eterna |
| Lilly USA, LLC | $679.17 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $555.25 | 2021-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $550.09 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $532.17 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $418.39 | 2022-2025 | |
| Edwards Lifesciences Corporation | $302.02 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $229.22 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.22 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $200.62 | 2021-2024 | |
| Glaxosmithkline, LLC. | $179.77 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Astellas Pharma US INC | $160.32 | 2022-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $138.56 | 2021-2024 | Xarelto |
| Esperion Therapeutics, INC. | $128.68 | 2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Radcliffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.